Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Liver" returned 9 results:


A 36 month multi-center, open-label, randomized, comparator study to evaluate the efficacy and safety of everolimus immunosuppression treatment in liver transplantation for hepatocellular carcinoma exceeding Milan criteria
Principal Investigator(s): Dr. Sander Florman

Assessment of Response of Unresectable Hepatocellular Carcinoma Chemoembolization and Stereotactic Body Radiation Therapy
Principal Investigator(s): Dr. Michael H. Buckstein

A Phase Ib Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Carcinoma
Principal Investigator(s): Celina Ang

A Multicenter, randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Levantinib (E7080) versus Sorafenib in First Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma
Principal Investigator(s): Max W Sung

A Prospective Randomized Clinical Trial on 90Yttrium Trans-Arterial Radio-Embolization (Therasphere®) vs. Standard Of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Principal Investigator(s): Dr. Myron Schwartz

A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)
Principal Investigator(s): Celina Ang

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy
Principal Investigator(s): Dr. Celina Ang

Phase 3 Prospective, Randomized, Blinded And Controlled Investigation Of Hepasphere/Quadrasphere Microspheres For Delivery Of Doxorubicin For The Treatment Of Hepatocellular Cancer
Principal Investigator(s): Edward Kim

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Principal Investigator(s): Myron Schwartz